# A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-5817 Injection

> **NCT06934408** · PHASE1 · RECRUITING · sponsor: **Fujian Shengdi Pharmaceutical Co., Ltd.** · enrollment: 92 (estimated)

## Conditions studied

- Obesity
- Overweight

## Interventions

- **DRUG:** HRS-5817 Injection
- **DRUG:** HRS-5817 Injection Placebo

## Key facts

- **NCT ID:** NCT06934408
- **Lead sponsor:** Fujian Shengdi Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-08
- **Primary completion:** 2027-04
- **Final completion:** 2027-04
- **Target enrollment:** 92 (ESTIMATED)
- **Last updated:** 2025-11-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06934408

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06934408, "A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-5817 Injection". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06934408. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*